Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiative capture of polarized neutrons by polarized protons at Tn=183 MeV.
Xu G, Pate SF, Bloch C, Vigdor SE, Bowyer SM, Bowyer TW, Jacobs WW, Meyer HO, Pierce E, Sowinski J, Whiddon C, Wissink SW, Jolivette PL, Pickar MA. Xu G, et al. Among authors: pierce e. Phys Rev C Nucl Phys. 1995 Dec;52(6):2859-2874. doi: 10.1103/physrevc.52.2859. Phys Rev C Nucl Phys. 1995. PMID: 9970836 No abstract available.
Mitochondrial DNA variant detection in over 6,500 rare disease families by the systematic analysis of exome and genome sequencing data resolves undiagnosed cases.
Stenton SL, Laricchia K, Lake NJ, Chaluvadi S, Ganesh V, DiTroia S, Osei-Owusu I, Pais L, O'Heir E, Austin-Tse C, O'Leary M, Abu Shanap M, Barrows C, Berger S, Bönnemann CG, Bujakowska KM, Campagna DR, Compton AG, Donkervoort S, Fleming MD, Gallacher L, Gleeson JG, Haliloglu G, Pierce EA, Place EM, Sankaran VG, Shimamura A, Stark Z, Tan TY, Thorburn DR, White SM; Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium; Vilain E, Lek M, Rehm HL, O'Donnell-Luria A. Stenton SL, et al. Among authors: pierce ea. medRxiv [Preprint]. 2024 Dec 26:2024.12.22.24319370. doi: 10.1101/2024.12.22.24319370. medRxiv. 2024. PMID: 39763565 Free PMC article. Preprint.
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Blauvelt A, et al. Among authors: pierce e. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. J Dermatolog Treat. 2025. PMID: 39761965 Free article.
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.
Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, Elmaraghy H, Atwater AR, Pierce E, Xu C, Agell H, Gil EG, Simpson E. Guttman-Yassky E, et al. Among authors: pierce e. J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414-5. doi: 10.1016/j.jaad.2024.12.026. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39733939
Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis.
Yosipovitch G, de Bruin-Weller M, Wiseman M, Elberling J, Gutermuth J, Pierce E, Montmayeur S, Yang FE, Ding Y, Bardolet L, Chisolm S. Yosipovitch G, et al. Among authors: pierce e. Clin Exp Dermatol. 2024 Dec 16:llae541. doi: 10.1093/ced/llae541. Online ahead of print. Clin Exp Dermatol. 2024. PMID: 39680511
An alternate route for cellulose microfibril biosynthesis in plants.
Roberts EM, Yuan K, Chaves AM, Pierce ET, Cresswell R, Dupree R, Yu X, Blanton RL, Wu SZ, Bezanilla M, Dupree P, Haigler CH, Roberts AW. Roberts EM, et al. Among authors: pierce et. Sci Adv. 2024 Dec 13;10(50):eadr5188. doi: 10.1126/sciadv.adr5188. Epub 2024 Dec 13. Sci Adv. 2024. PMID: 39671498 Free PMC article.
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
Simpson E, Fernández-Peñas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, Agell H, Casillas M, Ding Y, Yang FE, Pierce E, Bieber T. Simpson E, et al. Among authors: pierce e. Adv Ther. 2024 Dec 5. doi: 10.1007/s12325-024-03010-9. Online ahead of print. Adv Ther. 2024. PMID: 39636571 No abstract available.
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.
Santoni M, Büttner T, Rescigno P, Fiala O, Cavasin N, Basso U, Taha T, Massari F, Myint ZW, Formisano L, Galli L, Scagliarini S, Matrana MR, Facchini G, Bamias A, Messina C, Zacchi F, Manneh RK, Roviello G, Santini D, Poprach A, Navratil J, Uher M, Calabrò F, Pierce E, Berardi R, Aurilio G, Zakopoulou R, Rizzo A, Ansari J, Rizzo M, Bisonni R, Mollica V, Incorvaia L, Spinelli G, Jiang XY, Chandler RA, Grillone F, Morelli F, Buti S, Maluf FC, Marques Monteiro FS, Battelli N, Porta C, Caffo O, Soares A. Santoni M, et al. Among authors: pierce e. Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00253-0. doi: 10.1016/j.euo.2024.11.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39613567 Free article.
569 results